Clinical TrialApr 30, 2026, 09:02 AM
FATE FT819 SLE data shows clinically meaningful improvements
AI Summary
Fate Therapeutics announced that clinical data for its off-the-shelf CAR T-cell product candidate, FT819, in systemic lupus erythematosus (SLE) will be presented at the Congress of Clinical Rheumatology – East meeting. The presentation includes safety, efficacy, and translational data from 13 SLE patients, with the first 10 patients in Regimen A showing clinically meaningful improvements in disease activity and patient-reported outcomes following a single dose. These positive responses were observed early and maintained over time.
Key Highlights
- FT819 data from 13 SLE patients presented at CCR-East meeting.
- First 10 SLE patients in Regimen A showed clinically meaningful improvements.
- SLEDAI-2K scores decreased by 13 points from baseline at Month 6.
- PGA scores decreased by 1.75 points from baseline at Month 6.
- UPCr levels decreased by 0.90 mg/mg at Month 3 and 1.14 mg/mg at Month 6.
- FACIT-Fatigue scores improved by 23.4 points at Month 3 and 24.3 points at Month 6.